Satellos Bioscience (MSLE) Debt Ratio (2024 - 2025)
Satellos Bioscience's (MSLE) quarterly Debt Ratio came in at 0.07 in Q4 2025, up 143.82% year-on-year from 0.03 in Q4 2024, and up 143.82% on a QoQ basis from 0.03 in Q4 2024.
Satellos Bioscience (MSLE) Debt Ratio (2024 - 2025) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Debt Ratio data on file, last reported at 0.07 in Q4 2025.
- On a quarterly basis, Debt Ratio rose 143.82% year-over-year to 0.07 in Q4 2025; TTM through Dec 2025 was 0.07, a 143.82% increase from a year earlier, with the FY2025 full-year figure at 0.07, changed N/A from the prior year.
- Debt Ratio for Q4 2025 stood at 0.07, up from 0.03 in the prior quarter.
- Over the last five years, Debt Ratio for MSLE reached as high as 0.07 in Q4 2025 and fell as low as 0.03 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | Satellos Bioscience | 175.69 Mn | 175.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.07 |
| Dec 31, 2024 | 0.03 |